Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanguine Corporation has signed a letter of commitment to license its PHER-O2 technology to Rockland Technimed for a collaborative effort to significantly enhance stroke and tumor diagnosis and treatment.
Subscribe to our email newsletter
It is reported that Technimed’s magnetic resonance imaging (MRI) technology and product Oxy-17 effectively renders an unaltered MRI scanner into a positron emission tomography (PET), PET/CT like metabolic imager using ultra pure oxygen, isotopically enriched and naturally occurring in atmospheric air, delivered to target tissue of interest. The ability to follow cellular respiration in real-time using an unaltered MRI in these patients is a paradigm shift in the management of these patients, noted Sanguine.
As part of the agreement, Sanguine has agreed to license the technology and know-how for PHER-02 to Rockland for use and further development by Rockland Technimed in conjunction with its imaging technology.
Thomas Drees, CEO of Sanguine, said: “We concluded that the best way to move both technologies and products ahead was to enter into a licensing arrangement that will accomplish that. Our team feels that a relationship with Rockland Technimed provides us with a unique opportunity to move the company’s focus of PHER-O2 into intravenous use.”